Strategies for Evaluation of Antiviral Agents Against Epstein-Barr Virus in Culture
Evaluation of antiviral agents against Epstein-Barr virus (EBV) has been hampered by the lack of a permissive cell system for the replication of this virus. The extent of EBV replication detected in producer cell lines (P3HR-1 and B95-8) is limited: only a small fraction (<10%) of the cell population spontaneously produces virus at any given time. Attempts to increase the virus yield by manipulation of the culture conditions, such as temperature shifts, exposure to halogenated pyrimidines, such as BUdR and IUdR, and X-ray, have not been very successful. Superinfection of Raji (a nonvirus-producer line) cells with P3HR-1 virus enhances EBV replication and provides a more efficient system for evaluation of antiviral drugs. However, this method requires infection with virus isolated from a large quantity of culture fluids of P3HR-1 cells The virus yield varies from preparation to preparation. In addition, the system is not practical for large-scale drug screening.
KeywordsRaji Cell Virus Yield Trypan Blue Exclusion Method Antigen Synthesis Benchtop Centrifuge
- 1.zur Hausen, H., O’Neill, F. J., and Freeze, J. K. (1978) Persisting oncogenic herpesvirus induced by the tumor promoter TPA. Nature (London) 272, 373–375.Google Scholar
- 5.Mar, E. C. and Lin, J. C. (1996) Effects of temporal treatments of nucleoside analogs on replication of Epstein-Barr virus. Ninth International Conference on Antiviral Research, Fukushima, Japan, May 19–24.Google Scholar
- 8.Reed, L. J. and Muench, H. (1938) A simple method of estimating fifty percent endpoints. Am. J. Hygiene 27, 493–497.Google Scholar
- 9.Nonoyama, M. and Pagano, J. S. (1971) Detection of Epstein-Barr viral genome in nonproductive cells. Nature (London) New Biol. 233, 103–106.Google Scholar